Targeted biological therapies for Graveś disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab

Clinical Endocrinology

Volumn 74, Issue 1, 2011, Pages 1-8

  Hegedüs, Laszlo ^a   Smith, Terry J ^b   Douglas, Raymond S ^b   Nielsen, Claus H ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AUTOANTIBODY; CHLORPHENIRAMINE; CLEMASTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; THIAMAZOLE;

ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; BIOLOGICAL THERAPY; CHILL; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; FEVER; GRAVES DISEASE; HEART ARREST; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTENSION; IMMUNE RESPONSE; IRIDOCYCLITIS; METHODOLOGY; NAUSEA; POLYARTHRITIS; PRIORITY JOURNAL; RECURRENT FEVER; REMISSION; SERUM SICKNESS; SINUS TACHYCARDIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID FUNCTION; TREATMENT RESPONSE; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL;

EID: 78650411552     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03806.x     Document Type: Article

References (80)

1. Weetman, A.P., (2000) Graves' disease. The New England Journal of Medicine. 343, 1236-1248.
2. Brent, G.A., (2008) Clinical practice. Graves' disease. The New England Journal of Medicine, 358, 2594-2605.
3. Brix, T.H., Kyvik, K.O., Christensen, K., et al. (2001) Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. The Journal of Clinical Endocrinology and Metabolism, 86, 930-934.
4. Hegedus, L., (2009) Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. Endocrinology and Metabolism Clinics of North America, 38, 355-371. ix.
5. Wartofsky, L., Glinoer, D., Solomon, B., et al. (1991) Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid, 1, 129-135.
6. Bartalena, L., &, Tanda, M.L., (2009) Clinical practice. Graves' ophthalmopathy. The New England Journal of Medicine. 360, 994-1001.
7. Stiebel-Kalish, H., Robenshtok, E., Hasanreisoglu, M., et al. (2009) Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. The Journal of Clinical Endocrinology and Metabolism, 94, 2708-2716.
8. Watt, T., Groenvold, M., Rasmussen, A.K., et al. (2006) Quality of life in patients with benign thyroid disorders. A review. European Journal of Endocrinology, 154, 501-510.
9. El Fassi, D., Nielsen, C.H., Hasselbalch, H.C., et al. (2006) Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid, 16, 709-710.
10. Salvi, M., Vannucchi, G., Campi, I., et al. (2006) Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology, 154, 511-517.
11. Reff, M.E., Carner, K., &, Chambers, K.S., (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435-445.
12. Boye, J., Elter, T., &, Engert, A., (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology, 14, 520-535.
13. Nielsen, C.H., El Fassi, D., Hasselbalch, H.C., et al. (2007) B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opinion in Biological Therapy, 7, 1061-1078.
14. Levine, T.D., &, Pestronk, A., (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology, 52, 1701-1704.
15. Edwards, J.C., &, Cambridge, G., (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 40, 205-211.
16. Edwards, J.C., Cambridge, G., &, Abrahams, V.M., (1999) Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology, 97, 188-196.
17. Hasselbalch, H.C., (2003) B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunology Letters, 88, 85-86.
18. Wang, S.H., &, Baker Jr, J.R., (2006) Targeting B cells in Graves' disease. Endocrinology, 147, 4559-4560.
19. Pritchard, J., Han, R., Horst, N., et al. (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the IGF-1 receptor pathway. Journal of Immunology, 170, 6348-6354.
20. Pritchard, J., Horst, N., Cruikshank, W., et al. (2002) Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. Journal of Immunology, 168, 942-950.
21. Douglas, R.S., Gianoukakis, A.G., Kamat, S., et al. (2007) Aberrant expression of the IGF-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. Journal of Immunology, 178, 3281-3287.
22. Douglas, R.S., Naik, V., Hwang, C.J., et al. (2008) B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. Journal of Immunology, 181, 5768-5774.
23. Lanzavecchia, A., (1985) Antigen-specific interaction between T and B cells. Nature, 314, 537-539.
24. Takemura, S., Klimiuk, P.A., Braun, A., et al. (2001) T cell activation in rheumatoid synovium is B cell dependent. Journal of Immunology, 167, 4710-4718.
25. Serreze, D.V., Fleming, S.A., Chapman, H.D., et al. (1998) B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. Journal of Immunology, 161, 3912-3918.
26. Falcone, M., Lee, J., Patstone, G., et al. (1998) B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. Journal of Immunology 161, 1163-1168.
27. Hauser, S.L., Waubant, E., Arnold, D.L., et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New England Journal of Medicine, 358, 676-688. (Pubitemid 351240747)
28. Pescovitz, M.D., Greenbaum, C.J., Krause-Steinrauf, H., et al. (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. The New England Journal of Medicine, 361, 2143-2152.
29. Rifkin, I.R., Leadbetter, E.A., Beaudette, B.C., et al. (2000) Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. Journal of Immunology, 165, 1626-1633.
30. Nielsen, C.H., Leslie, R.G., Jepsen, B.S., et al. (2001) Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. European Journal of Immunology, 31, 2660-2668.
31. Nielsen, C.H., Hegedus, L., &, Leslie, R.G., (2004) Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. European Journal of Immunology, 34, 263-272.
32. Smeland, E.B., Blomhoff, H.K., Funderud, S., et al. (1989) Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. Journal of Experimental Medicine, 170, 1463-1468.
33. Skok, J., Poudrier, J., &, Gray, D., (1999) Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. Journal of Immunology, 163, 4284-4291.
34. Correale, J., Farez, M., &, Razzitte, G., (2008) Helminth infections associated with multiple sclerosis induce regulatory B cells. Annals of Neurology, 64, 187-199.
35. Fillatreau, S., Sweenie, C.H., McGeachy, M.J., et al. (2002) B cells regulate autoimmunity by provision of IL-10. Nature Immunology, 3, 944-950.
36. Mauri, C., Gray, D., Mushtaq, N., et al. (2003) Prevention of arthritis by interleukin 10-producing B cells. Journal of Experimental Medicine, 197, 489-501.
37. Parekh, V.V., Prasad, D.V., Banerjee, P.P., et al. (2003) B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8 + T cells: role of TGF-beta 1. Journal of Immunology, 170, 5897-5911.
38. Bouaziz, J.D., Yanaba, K., &, Tedder, T.F., (2008) Regulatory B cells as inhibitors of immune responses and inflammation. Immunological Reviews, 224, 201-214.
39. Armengol, M.P., Juan, M., Lucas-Martin, A., et al. (2001) Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. American Journal of Pathology, 159, 861-873.
40. Segundo, C., Rodriguez, C., Aguilar, M., et al. (2004) Differences in thyroid-infiltrating B lymphocytes in patients with Graves' disease: relationship to autoantibody detection. Thyroid, 14, 337-344.
41. El Fassi, D., Clemmensen, O., Nielsen, C.H., et al. (2007) Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. The Journal of Clinical Endocrinology and Metabolism, 92, 3762-3763.
42. El Fassi, D., Nielsen, C.H., Kjeldsen, J., et al. (2008) Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut, 57, 714-715.
43. Paran, D., Trej'o, L., &, Caspi, D., (2006) Clinical images: B cell depletion in the appendix following rituximab treatment. Arthritis and Rheumatism, 54, 2151.
44. Teng, Y.K., Levarht, E.W., Hashemi, M., et al. (2007) Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis and Rheumatism, 56, 3909-3918.
45. Nielsen, J.F., El Fassi, D., Nielsen, C.H., et al. (2009) Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy. Acta Ophthalmologica, 87, 927-929.
46. El Fassi, D., Nielsen, C.H., Bonnema, S.J., et al. (2007) B lymphocyte depletion with the monoclonal antibody Rituximab in Graves' disease. A controlled pilot study. The Journal of Clinical Endocrinology and Metabolism, 92, 1769-1772.
47. Salvi, M., Vannucchi, G., Campi, I., et al. (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology, 156, 33-40.
48. Heemstra, K.A., Toes, R.E., Sepers, J., et al. (2008) Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology, 159, 609-615.
49. El Fassi, D., Banga, J.P., Gilbert, J.A., et al. (2009) Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clinical Immunology, 130, 252-258.
50. Huang, H., Benoist, C., &, Mathis, D., (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proceedings of the National Academy of Science of the United States of America, 107, 4658-4663.
51. Huber, G.K., Weinstein, S.P., Graves, P.N., et al. (1992) The positive regulation of human thyrotropin (TSH) receptor messenger ribonucleic acid by recombinant human TSH is at the intranuclear level. Endocrinology, 130, 2858-2864.
52. Chazenbalk, G.D., Pichurin, P., Chen, C.R., et al. (2002) Thyroid-stimulating autoantibodies in Graves' disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. Journal of Clinical Investigation, 110, 209-217.
53. De, B.A., Sansone, D., Coronella, C., et al. (2005) Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. Clinical Endocrinology (Oxf), 62, 24-29.
54. Smith, T.J., &, Hoa, N., (2004) Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. The Journal of Clinical Endocrinology and Metabolism, 89, 5076-5080.
55. Leandro, M.J., Edwards, J.C., &, Cambridge, G., (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Annals of Rheumatic Diseases, 61, 883-888.
56. Looney, R.J., Anolik, J.H., Campbell, D., et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis and Rheumatism, 50, 2580-2589.
57. Edwards, J.C., Szczepanski, L., Szechinski, J., et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine, 350, 2572-2581. (Pubitemid 38758544)
58. Gottenberg, J.E., Guillevin, L., Lambotte, O., et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Annals of Rheumatic Diseases, 64, 913-920.
59. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and Rheumatism, 54, 1390-1400.
60. Cambridge, G., Leandro, M.J., Teodorescu, M., et al. (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis and Rheumatism, 54, 3612-3622.
61. Vallerskog, T., Gunnarsson, I., Widhe, M., et al. (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clinical Immunology, 122, 62-74.
62. Cohen, S.B., Emery, P., Greenwald, M.W., et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism, 54, 2793-2806.
63. Moser, K., Muehlinghaus, G., Manz, R., et al. (2006) Long-lived plasma cells in immunity and immunopathology. Immunology Letters, 103, 83-85.
64. Stasi, R., Stipa, E., Del Poeta, G., et al. (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford), 45, 1432-1436.
65. Douglas, R.S., Tsirbas, A., Gordon, M., et al. (2009) Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Archives of Ophthalmology, 127, 1155-1160.
66. Khanna, D., Chong, K.K., Afifyan, N.F., et al. (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology, 117, 133-139.
67. Krassas, G.E., Stafilidou, A., &, Boboridis, K.G., (2010) Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clinical Endocrinology, in press.
68. Serreze, D.V., Chapman, H.D., Varnum, D.S., et al. (1996) B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. Journal of Experimental Medicine 184, 2049-2053.
69. Guo, J., Wang, Y., Rapoport, B., et al. (2000) Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts co-expressing TPO and MHC class II. Clinical and Experimental Immunology, 119, 38-46.
70. Toubi, E., Kessel, A., Slobodin, G., et al. (2007) Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Annals of Rheumatic Diseases, 66, 818-820.
71. Keren, Z., Braun-Moscovici, Y., Markovits, D., et al. (2009) Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network. Clinical Immunology, 113, 108-116.
72. Bower, M., Veralitch, O., Szydlo, R., et al. (2009) Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood, 113, 4521-4524.
73. Tamimoto, Y., Horiuchi, T., Tsukamoto, H., et al. (2008) A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology, 47, 821-827.
74. Ferraro, A.J., Drayson, M.T., Savage, C.O., et al. (2008) Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. European Journal of Immunology, 38, 292-298.
75. Anolik, J.H., Barnard, J., Cappione, A., et al. (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis and Rheumatism, 50, 3580-3590.
76. Smith, T.J., (2007) B cell depletion in Graves' disease: the right answer for the wrong question? The Journal of Clinical Endocrinology and Metabolism, 92, 1620-1622.
77. Hegedüs, L., (2010) Optimizing remission rates using antithyroid drugs for Graves' disease. Clinical Endocrinology, in press PMID:20050856.
78. Goetz, M., Atreya, R., Ghalibafian, M., et al. (2007) Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflammatory Bowel Diseases 13, 1365-1368.
79. Banga, J.P., Nielsen, C.H., Gilbert, J.A., et al. (2008) Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials. Thyroid, 18, 973-981.
80. Bahn, R., (2010) Graves' ophthalmopathy. The New England Journal of Medicine, 362, 726-738.